Skip to content
ChickenStockChickenStock
Research085660
Chabiotech logo

Chabiotech (085660) stock

KOSDAQ · Health Care Providers & Services

KRW 7,490-0.13%(-10)

As of Nov 16, 9:43 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-189.41x

Net loss — not comparable

P/B

1.68x

P/S

0.56x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 13, 2026KRW 316.4 billion-KRW 28.2 billionKRW 30.7 billion+5.9%
Q1 2026Consolidated · Filed May 15, 2026KRW 329.7 billion-KRW 30.7 billion-KRW 2.6 billion+8.4%
Q4 2025Consolidated · Filed Jun 9, 2026KRW 346.5 billion-KRW 7.4 billion-KRW 35.3 billion—
Q3 2025Consolidated · Filed Nov 13, 2025KRW 318.7 billion-KRW 8.1 billion-KRW 9.2 billion+17.2%
Q2 2025Consolidated · Filed Aug 13, 2025KRW 298.9 billion-KRW 20.8 billion-KRW 75.2 billion+12.9%
Q1 2025Consolidated · Filed May 16, 2025KRW 304.1 billion-KRW 12.5 billion-KRW 27 billion+30.9%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Jun 9, 2026KRW 1.3 trillion-KRW 48.8 billion-KRW 146.7 billion—
FY2024Consolidated · Filed Aug 13, 2025KRW 1 trillion-KRW 59.7 billion-KRW 14.6 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
4.18%
Of trading value on Nov 13, 2026
Short-sale value
KRW 140 million
Previous 20-day average 6.92%
Net short position
74,386 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
6,266,090 shares
As of Nov 13, 2026 · 6.74% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20264.18%KRW 140 million
Nov 12, 20264.56%KRW 70 million
Nov 11, 202610.70%KRW 210 million
Nov 10, 20264.19%KRW 80 million
Nov 9, 20268.25%KRW 260 million
Nov 6, 20269.84%KRW 460 million
Nov 5, 20267.31%KRW 420 million
Nov 4, 20267.78%KRW 190 million
Nov 3, 202610.85%KRW 170 million
Nov 2, 20264.86%KRW 60 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Chabiotech (085660) stock information

KOSDAQ

Chabiotech (085660) is listed on KOSDAQ. Its market capitalization is about KRW 696.4 billion. On trailing-twelve-month earnings the P/E ratio is -189.41, and the P/B ratio is 1.68. Return on equity is -0.9%. These figures are computed in-house from official filings and are reference information only.

Chabiotech — frequently asked questions

What is the P/E ratio of Chabiotech (085660)?
On a trailing-twelve-month basis, 085660 trades at a P/E ratio of -189.41. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Chabiotech?
085660 has a market capitalization of about KRW 696.4 billion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.